Brent,
May not only RAIN keep defying gravity, but all of our portfolio products.
I did a little checking on those biotechs you mentioned ,and I strongly agree that PRLN is the better of the two. They seemingly had their big dip in January, briefly getting under 1 again, but have
gradually in a stepwise fashion moved forward since, with a fairly steady hold through this brutal month. The prostate cancer test should help bring some income in with a current EPS of -.84. However,
the pn355 stuff is a long way from being worth anything profitwise. It sounds interesting, inhibiting the C-MOS protein in HIV 1, which is what allows these to replicate in T-cells and as such for all intents
and purposes kill off an effective immune system. Basically, if replication can be stopped, so theoretically can HIV1. This is all very encouraging, and as such clinical trials apparently are getting underway,
but it is a heck of a long way from being FDA approved and available for use. Also, with so much technology out there, there are many other areas which also sound quite interesting in the war against
HIV which seem to be a lot further along. There is promise, but lots of gamble, although I'm sure there would be other applications, as well. The financial positive is that with just over 4 million shares and
other sources of income, they sound poised for further movement up from the recent 3 and 13/32 in the near to intermediate future assuming the market cooperates(a big if).
I wasn't as impressed with stressgen. Another one which sounds fairly impressive right now is NMPS, with lots of tests coming out to aid with nearterm profitability, most recently getting approval for bladder
cancer testing. They are well down from their annual high of 18(annual low of 2 and 3/4) during the recent crunching, at about 9and 3/8 at this point, but with earnings at a loss of the mid.30s and just under 10 million
shares, they especially appear ready for a move upward(with market cooperation), possibly into the mid-teens over the next several months, if not more. Let it be noted, at this point I don't own any of the above
mentioned, but I'm basing my amateur opinion on apparent immediate usefulness(and as such profits) on the products.
For speculative purposes, the one that I had mentioned to Dennis was ATIS, and I feel very strongly that this one is going to be a big money maker over the next 1-2 years. Of course, at this point with the
market doing funny things, a little watching and waiting might be prudent to get reasonable prices. They are likely to get approval on dermagraft tc for use with burn victims by 11/96, and for bigger possible financial
pushing, are likely to complete their thus far 100% study on treating diabetic foot ulcers with dermagraft(thus far, complete healing with no recurrence in 14-28 month period). If this study is completed by year's end with
the current results holding, and with FDA agreeing to expedited review, they could reasonably have approval of this product by next summer/fall. This one is the key, because they would have no competition in an
industry valued at over $1 billion in the US alone, and they have agreement with Smith and Nephew, thus allowing global access. The IBD indicates over the last 2 months that corporate sponsorship has increased
as well, moving up to 12 I believe as of last week's IBD. The other thing I like about this product is that medically it is a lot easier to evaluate than drugs....no centrally acting effects or side effects to monitor, thus expediting
the whole process if all looks good.
Anyway, I'm going to stop on this stuff, because it's not really supposed to be a biotech forum, and I am a big RAIN fan as well as speculator on ATIS. You may want to further investigate ISIP as well, as for the 3-5 year
range their wide range of tech and patents could take them far.
I'm likely going to get a chance to check out the DW RAIN in early 8/96 prior to the grand opening. I'll keep you posted...if you happen to be reading as well Dennis, and if the biotech stuff didn't put you to sleep, obviously
I'll be thinking about you while RAINing.
Regards, and please let me know your thoughts on the biotech stuff, Brent, although maybe we should discuss more in a different forum for obvious reasons,
Marshall
|
